181 related articles for article (PubMed ID: 18340669)
1. Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
Power UF
J Clin Virol; 2008 Jan; 41(1):38-44. PubMed ID: 18340669
[TBL] [Abstract][Full Text] [Related]
2. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
Ascough S; Paterson S; Chiu C
Front Immunol; 2018; 9():323. PubMed ID: 29552008
[TBL] [Abstract][Full Text] [Related]
3. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.
González PA; Bueno SM; Riedel CA; Kalergis AM
Curr Med Chem; 2009; 16(34):4609-25. PubMed ID: 19903147
[TBL] [Abstract][Full Text] [Related]
4. New insights for development of a safe and protective RSV vaccine.
Blanco JC; Boukhvalova MS; Shirey KA; Prince GA; Vogel SN
Hum Vaccin; 2010 Jun; 6(6):482-92. PubMed ID: 20671419
[TBL] [Abstract][Full Text] [Related]
5. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of subunit-based RSV vaccines.
Jaberolansar N; Toth I; Young PR; Skwarczynski M
Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
[TBL] [Abstract][Full Text] [Related]
7. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
[TBL] [Abstract][Full Text] [Related]
8. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.
Kim JY; Chang J
Yonsei Med J; 2016 Jul; 57(4):809-16. PubMed ID: 27189271
[TBL] [Abstract][Full Text] [Related]
9. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
Sarkar I; Garg R; van Drunen Littel-van den Hurk S
Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
[TBL] [Abstract][Full Text] [Related]
10. Identifying targets in the hunt for effective respiratory syncytial virus interventions.
Tayyari F; Hegele RG
Expert Rev Respir Med; 2012 Apr; 6(2):215-22. PubMed ID: 22455493
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
12. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
13. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.
Lee YN; Suk Hwang H; Kim MC; Lee YT; Cho MK; Kwon YM; Seok Lee J; Plemper RK; Kang SM
Virology; 2015 Feb; 476():217-225. PubMed ID: 25553517
[TBL] [Abstract][Full Text] [Related]
14. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
15. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
16. Host Responses to Respiratory Syncytial Virus Infection.
Agac A; Kolbe SM; Ludlow M; Osterhaus ADME; Meineke R; Rimmelzwaan GF
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896776
[TBL] [Abstract][Full Text] [Related]
17. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
18. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
Jorquera PA; Anderson L; Tripp RA
Expert Rev Vaccines; 2016; 15(2):173-87. PubMed ID: 26641318
[TBL] [Abstract][Full Text] [Related]
19. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.
Grieves JL; Yin Z; Garcia-Sastre A; Mena I; Peeples ME; Risman HP; Federman H; Sandoval MJ; Durbin RK; Durbin JE
Vaccine; 2018 Jun; 36(26):3842-3852. PubMed ID: 29779923
[TBL] [Abstract][Full Text] [Related]
20. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
